RCM
CTOR

Rivernorth Capital Management’s Citius Oncology CTOR Stock Holding History

Rivernorth Capital Management’s Portfolio CTOR Stock Details CTOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-350,000
Closed -$3.98M – 418
2024
Q2 		$3.98M Hold
350,000
– – 0.19% 108
2024
Q1 		$3.87M Hold
350,000
– – 0.19% 108
2023
Q4 		$3.83M Hold
350,000
– – 0.18% 103
2023
Q3 		$3.77M Hold
350,000
– – 0.2% 107
2023
Q2 		$3.67M Buy
+350,000
New +$3.66M 0.18% 104

Other funds holding CTOR

YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Rivernorth Capital Management's CTOR Position: Q3 2024 in Review

Rivernorth Capital Management sold out of Citius Oncology (CTOR) in Q3 2024, closing a stake of 350,000 shares — an estimated $3.98M sold.

Rivernorth Capital Management first reported a position in CTOR in Q2 2023 and held it in 5 quarters. The position peaked at $3.98M in Q2 2024. 7 funds tracked by Wall St. Rank hold CTOR as of Q3 2024.

  • Rivernorth Capital Management reported no remaining Citius Oncology position as of Q3 2024 after selling out during the quarter.
  • Rivernorth Capital Management sold 350,000 Citius Oncology shares in Q3 2024, an estimated $3.98M.
  • Rivernorth Capital Management first reported a position in Citius Oncology in Q2 2023 and held it in 5 quarters.
  • Rivernorth Capital Management's Citius Oncology position peaked at $3.98M in Q2 2024.
  • 7 funds tracked by Wall St. Rank held Citius Oncology as of Q3 2024.

Based on Rivernorth Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.